Comparative aspects of canine and human inflammatory breast cancer by Raposo, T.P. et al.
1 
 
Comparative Aspects of Canine and Human Inflammatory Breast Cancer 
 
Teresa P. Raposo, DVM, MSc, PhDa, Hugo Arias-Pulido, PhDb, Nabila Chaherc, MD, Steven 
N. Fiering, PhDd, David J. Argyle, BVMS, PhD, DECVIM-CA (Oncology), FRSE FRCVSe, 
Justina Prada DVM, MSc, PhDf,g, Isabel Pires DVM, MSc, PhDf,g, Felisbina Luísa Queiroga 
FL DVM, MSc, PhDf,h,i*  
a - Division of Cancer and Stem Cells, University of Nottingham, United Kingdom; b - 
Department of Microbiology and Immunology. Geisel School of Medicine at Dartmouth, 
Lebanon, New Hampshire 03756, USA; c - Department of Pathology, Centre Pierre et Marie 
Curie, 1, Avenue Battendier, Place May 1st, Algiers, Algeria; d - Department of 
Microbiology and Immunology, Department of Genetics, and Norris Cotton Cancer Center. 
Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire 03756, USA; e – The 
Royal (Dick) School of Veterinary Studies and Roslin Institute, Easter Bush Campus, 
Midlothian, University of Edinburgh, United Kingdom; f - Departament of Veterinary 
Sciences, University of Trás-os-Montes and Alto Douro, Vila Real, Portugal; g- Animal and 
Veterinary research Centre (CECAV), University of Trás-os-Montes and Alto Douro, Vila 
Real, Portugal; h- Center for the Study of Animal Sciences, CECA-ICETA, University of 
Porto, Porto, Portugal; i- Center for Research and Technology of Agro-Environment and 
Biological Sciences, University of Trás-os-Montes and Alto Douro, Vila Real, Portugal 
 
Corresponding author* - Felisbina Luísa Queiroga, Departament of Veterinary Sciences, 
University of Trás-os-Montes and Alto Douro, Quinta de Prados,Vila Real, Portugal  
e-mail: fqueirog@utad.pt; Tel: 00351 259350633 
  
2 
 
Abstract 
Inflammatory breast cancer in humans (IBC) is the most aggressive form of 
mammary gland cancer and shares clinical, pathological and molecular patterns of disease 
with canine inflammatory mammary carcinoma (CIMC). Despite the use of multimodal 
therapeutic approaches, including targeted therapies, the prognostic for IBC/CIMC remains 
poor. The aim of this review is to critically analyze IBC and CIMC in terms of biology and 
clinical features. While rodent cancer models have formed the basis of our understanding of 
cancer biology, the translation of this knowledge into improved outcomes has been limited.  
However, it is possible that a comparative “one health” approach to research, using a natural 
canine model of the disease, may help advanced our knowledge on the biology of the disease. 
This will translate into better clinical outcomes for both species. We propose that CIMC has 
the potential to be a useful model for developing and testing novel therapies for IBC. Further, 
this strategy could significantly improve and accelerate the design and establishment of new 
clinical trials to identify novel and improved therapies for this devastating disease in a more 
predictable way. 
Keywords: Inflammatory breast cancer; Comparative Oncology; Dog 
 
1. Introduction 
Dogs spontaneously develop cancers that share the biology and heterogeneity of 
cancers found in humans, including many clinical, molecular and pathological characteristics. 
Canine cancers are often relatively large tumors that develop spontaneously in large outbred 
mammals; are genetically complex and diverse; exist in the presence of an intact immune 
system, with complex interactions between the host immune system and tumor cells; have 
significant tumor heterogeneity both within patients and between patients; develop 
therapeutic resistance and metastasize to distant sites. The natural history and potential 
clinical use of cancers in companion dogs in general is out of the scope of this review, and 
have been extensively reviewed elsewhere [1-4]. 
Inflammatory breast cancer in humans (IBC) and the corresponding canine disease, 
canine inflammatory mammary carcinoma (CIMC), are the most aggressive type of 
mammary cancer in both species with short survival times after diagnosis [4-6]. In humans, 
IBC was first described in 1814 by Charles Bell as a painful breast tumor with a poor 
prognosis, presenting purple discoloration of the overlying skin [7]. In 1924 the designation 
"inflammatory breast cancer" was applied by Lee and Tannenbaum, who provided a clinical 
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description of the malignancy [8]. IBC is a rare and highly metastatic type of breast cancer 
comprising less than 3% of human breast cancer cases in the USA [9] with higher incidence 
observed in Northern Africa where the incidence varies from approximately 7% in Tunisia 
[10] to 11% in Egypt [11] . The reasons of such high incidence in this part of the world 
remain unknown. IBC is primarily a clinical adjunct to the histopathological diagnosis of 
breast cancer. IBC presents unique histopathological and clinical features for both humans 
and animals: edema, erythema, firmness, painful sensation, warmth of the mammary glands 
coupled with histological confirmation of tumor invasion of dermal lymphatic vessels 
[12,13]. Inflammatory mammary carcinoma in companion animals was initially described in 
dogs [14] and more recently in cats [15]. In a study at the Complutense University in Madrid, 
Spain, the reported prevalence of CIMC among dogs presenting for local consultation with 
mammary gland tumors and dysplasias was reported to be 7.6% [16]. Based on clinical and 
histological similarities, the possibility of using CIMC as a model to study IBC has been 
proposed by several authors [16-19]. The comparative aspects between IBC and CIMC 
including the etiology, molecular biology, diagnosis, treatment and prognosis, supporting the 
rationale for using CIMC as a model for IBC are summarized and analyzed in Table 1 
[6,14,20-52]. The effect of hormones on the etiology of CIMC and IBC is summarized in 
Table 2 [53-60] 
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Table 1 Comparative aspects between IBC and CIMC, including the etiology, molecular biology, diagnosis, treatment, and prognosis, supporting the rationale for using 
CIMC as a model for IBC. 
 CIMC- Comments Reference 
Clinical 
signs 
 Edema, erythema, firmness, warmth, pain 
 
 [14] 
Diagnosis  Clinical signs and invasion of dermal lymphatic vessels  Dermal lymphatic vessel invasion is a hallmark of CIMC [20] 
Viral 
etiology 
 Not yet investigated in CIMC. Absence of MMTV does not support a role in non-
CIMC. 
 [21] 
Cytokine 
activity 
 Serum levels of IL-10, IL-8 increased in CIMC vs non-CIMC.  Reduced case number (N=7)  [22] 
Molecular 
profiling 
 IPC-366 CIMC cell line: E-cadherin and COX-2 overexpression, ER-,PR-,HER2- 
 Increased relative gene expression of COX-2, VEGF, SNCG, Tribbles1 and CSF1R in 
CIMC versus non-CIMC tumors  
 Distinct nuclear subcellular expression of CCR2 was observed in CIMC vs non-CIMC 
CMT cases (P<.001)  
  
 
 Differential gene expression of CSF1R in CIMC and non-
CIMC is not confirmed by IHC. 
[23] 
 
[24] 
 
[25] 
Therapeutic 
options 
 Surgical excision without diffuse presentation  
 Chemotherapy + Piroxicam 
 Only small case series have been reported, no clinical trials 
have been performed.  
[26] 
[6] 
Prognostic 
factors 
 Administration of medical treatment extends survival, but not significantly   Prognostic studies on CIMC are difficult to perform as most 
animals are euthanised due to the severity of disease, thus the 
cause of death  is not advanced metastatic disease. 
[6] 
 IBC   
Clinical 
signs 
 Edema, erythema, “Peau d’orange”, discoloration, firmness, pain.   [27] 
Diagnosis  Clinical signs and dermal lymphatic vessels invasion   Although very frequent, invasion of lymphatic dermal vessels 
is not specific. 
[28] 
Viral 
etiology 
Human papilomavirus (HPV) 
Human cytomegalovirus (HCMV) 
 Human mammary tumor virus  
 Although there is an association between viral titers and the 
biological aggressiveness of IBC, a causal relationship is still 
debated.  
[29] 
[30] 
[31,32] 
Cytokine 
activity 
 TNF, IL-10, IL-8   The cytokine activity was measured in conditioned media of 
CD14+PBMCs collected from axillary vein tributaries of IBC 
patients during surgery, but not in the serum. 
[33] 
Molecular 
profiling 
Sialyl Lewis underexpression and E-cadherin overexpression  
Overexpression of NF-κB target genes  
WISP3 inhibition and RhoC GTPase activation, which controls proliferation and invasion 
 COX-2 expression in IBC remains unstudied, with the 
exception of vitro studies on celecoxib resistant cell line 
SUM149-CER [34] and the role of COX-2- produced 
[36,37] 
[38]  
[39,40] 
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 BCSS, Breast Cancer Specific Survival; CMT - Canine Mammary Tumors; DFS - Disease Free survival; EGFR,epidermal growth factor receptor; IBC,  
inflammatory breast cancer; IHC, immunohistochemistry; PR, progesterone receptor; MMTV, mouse mammary tumor virus 
  
Repression of TGF-β  
Mutated genes associated with apoptosis inhibition and cell cycle: TP53 (62%), MYC 
(32%)  
Overexpression of the translation initiation factor eIF4GI in most IBCs  
 PD-L1 overexpression is frequent in IBC (38%) 
prostaglandin EP4 in regulating  invasion and proliferation of 
SUM149 [35] 
[41] 
[42] 
[43] 
[44] 
Therapeutic 
options 
Taxane-anthracycline-based neoadjuvant chemotherapy, surgery, radiotherapy  
For ER+ Patients, 5-year tamoxifen or aromatase inhibitors depending on their 
menopausal state  
 Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary HER2+ IBC  
  [45] 
[46] 
 
[47] 
Prognostic 
factors 
Triple negative hormone receptor status predicts poor survival  
In a TNBC cohort, IBC status is not an independent predictor of recurrence or overall 
survival  
EGFR+ patients have worse prognosis 
Stromal VEGF-A expression is associated with worse DFS and BCSS  
5-miRNA signature comprising miR-421, miR-486, miR-503, miR-720 and miR-1303 
predictive for IBC phenotype with an overall accuracy of 89%.  
 PD-L1 overexpression in IBC predicts complete pathological response to 
chemotherapy  
  [48] 
 
[49] 
[50] 
[51] 
[47,52]. 
[44] 
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Table 2 Hormones and 
receptors 
Results/Observations Comment Reference 
CIMC ER  All CIMC cases were ER negative  ER detected in normal mammary gland 
(5/5, 100%)) and few non-inflammatory 
malignant CMT (2/32, 6.3%) but not in 
CIMC 
[53-55] 
l 
ERβ  In CIMC cases, ERβ positive tumors were also AR positive. 
 Significant increases ERβ (P=.038) in CIMC (N=21) versus non-
CIMC (N=19) by immunohistochemistry. 
 Progressive increases in ERβ suggest a 
role in CIMC carcinogenesis 
[54,56] 
 
PR  Significantly increased expression in CIMC (N=21) versus non-
CIMC (N=19) by immunohistochemistry (P=.0037). 
 PR could also be involved in CIMC 
carcinogenesis 
[56] 
 
HER2/neu  HER2/neu significance is unclear  Caution is advised with adapting FDA 
approved kits for human HER2/neu 
detection 
[57,58] 
AR  Majority of CIMC showing positivity for  AR (13/14), versus (27/32) 
of non-CIMC tumors, most of which had low-moderate levels of 
expression 
 No statistically significant increases observed in terms of total score 
(Alfred system) for AR in CIMC (95.2% positive, 20/21) relative to 
non-CIMC (89.5%, 17/19) 
 Disparity in AR findings, possibly due to 
different methodology. Reduced numbers 
of CIMC cases for both groups. 
 
[54] 
 
 
[56] 
Aromatase  Significant increases in aromatase (P=.025) in CIMC (N=21) versus 
non-CIMC (N=19) by immunohistochemistry 
 Progressive increases of aromatase 
suggest a role in CIMC carcinogenesis. 
[56] 
 
Androstenedione  Serum and tumor tissue homogenates hormonal levels significantly 
higher in CIMC relative to non-CIMC 
 Serum and tumor homogenates levels correlate, with the exception of 
17β-Estradiol, which had lower serum levels in CIMC relatively to 
non-CIMC 
 
 Small number of CIMC cases for both 
studies (n=7,[53] , n=7 [54]) 
 Benign tumors not included [54] 
 Only measured hormonal levels in tumor 
tissue homogenates by ELISA[53]  
 
[53,54] 
DHEA 
17β-Estradiol 
Progesterone 
Testosterone 
Estrone sulfate 
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AR - Androgen Receptor; ER -- estrogen receptor, PR - progesterone receptor; DHEA - dehydroepiandrosterone 
 
 
Table 2 
(cont.) 
Hormones and 
receptors 
Results/Observations Comment Reference 
IBC ER 26% Triple negative (ER-,PR-,HER2-)  
34% Triple negative (17% basal-like, 17% claudin-low)  
Only ER is analysed in ER immunoexpression in 
IBC by immunohistochemistry. 
 
[59] 
[60] ERβ 
PR 
HER2/neu 
AR Not yet investigated in IBC   
Aromatase 
Androstenedione Serum levels of steroid hormones and prolactin are yet investigated in IBC.   
DHEA 
17β-Estradiol 
Progesterone 
Testosterone 
Estrone sulfate 
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2. Etiology 
2.1 Endocrine etiology 
The etiology of both IBC and CIMC is multifactorial, resulting from a combination 
of hormonal changes, accumulated genetic mutations [5] and environmental factors [61-63].  
Several studies have been performed using canines to detect the expression of steroid 
hormones and their receptors that could be implicated in the genesis of the abnormal 
mammary epithelial proliferation observed in CIMC and in canine mammary tumors overall 
[53-55]. Expression of estrogen receptor alpha (ER), estrogen receptor beta (ERβ) and 
androgen receptor (AR) was evaluated by immunohistochemistry in a series of CIMC and 
non-CIMC tumors [54]. In all CIMC cases (N=14), ER expression was absent and 13/14 
(93%) of cases were ERβ and also AR positive. Moreover, AR expression in CIMC was 
increased relative to non-CIMC and normal mammary gland [54]. A more recent study [56], 
using a quantitative scoring system generated by adding the percentage of positive cells and 
the intensity of immunolabelling (total score expressed as mean ± S.E.M.) showed significant 
increases in immunohistochemistry staining for aromatase (P=.025), an enzyme that converts 
androgens to estrogens in situ [64], and also ERβ (P=.038) and progesterone receptor (PR) 
(P=.0037) in CIMC (n=21) versus non-CIMC (n=19). However no differences were found for 
expression of AR between CIMC and non-CIMC [56]. This disparity in AR results studies 
[54,56] could be explained by the differences in scoring systems and tumor series used, as 
well as by an increase in the conversion of androgens to estrogens in CIMC through abundant 
aromatase expression and subsequent down-regulation of AR in the study by de Andres et al.  
Hormone serum levels of dehydroepiandrosterone, androstenedione, testosterone, 
progesterone and estrone sulfate were significantly higher in CIMC than in non-CIMC 
samples [53,54]. The abundance of steroid hormones might be an important contributing 
factor in the pathogenesis of CIMC by mechanisms of paracrine and/or autocrine action. 
Estrone sulfate in particular may be converted into estrone and estradiol by the enzyme 
steroid sulfatase [65] or can directly transactivate estrogen and androgen receptors [66] 
therefore magnifying the effects of steroid hormonal regulation in CIMC.  
In IBC, to the best of our knowledge, detailed imunoexpression of ER and β, AR 
and aromatase have not yet been reported in the literature. Of note, steroid hormones levels, 
including progesterone, androstenedione, testosterone, 17β-estradiol and estrone sulfate 
levels have been shown to be higher in the conditioned media of the IBC cell line SUM149 
than in the CIMC cell line IPC-366 by ELISA immunoassay [67]. This study demonstrated in 
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vitro secretion of steroid hormones (progesterone, androstenedione, testosterone, 17β-
estradiol and estrone sulfate) [67], suggesting a role for hormonal regulation in IBC. 
However, studies with clinical samples, including tumor tissue and serum from patients with 
non-IBC and patients with IBC would be required to confirm this hypothesis and overcome 
the inherent limitations associated with in vitro conditions.  
 
2.2 Viral etiology 
Regarding the role of infectious agents in the etiology of breast cancer, viral 
infections by high-risk human papillomavirus (HPV) have been identified in metaplastic 
mammary carcinomas [30], but a causal relationship has not been established. In patients 
with IBC, titers of human cytomegalovirus (HCMV) IgG antibodies were found to be higher 
than in non-IBC patients. The presence of HCMV has been suggested to be linked to the 
etiology and pathogenesis of IBC with HCMV playing an oncomodulatory role by infecting 
adjacent tissues, leading to overexpression and activation of NF-κB/p65 [29,68,69]. To 
support this hypothesis, A recent study that enrolled 91 patients with non-IBC and 44 with 
IBC reported DNA from HCMV and HPV-16 were the most detected viral DNAs in breast 
carcinoma tissues, although the frequency and prevalence of HCMV and human herpes virus 
type 8 (HHV-8) DNA were significantly higher in IBC than non-IBC tissue [70]. However, 
the high incidence found in this study could be due to cross-contamination during the 
handling and processing of tissue samples, and the isolation of viral DNA, as the measures to 
prevent cross-contamination were not disclosed, therefore casting doubt on its results. The 
absence of papillomavirus DNA has been confirmed in  normal canine mammary gland 
(N=5) and canine mammary tumors (CMT) (N=27). Whilst this suggests these viruses are not 
associated with canine mammary carcinogenesis, the small numbers of cases studied makes it 
impossible to rule out  [71].  
Mouse mammary tumor virus-like sequences (MMTV) have been associated with 
human breast cancer [72-74]. These sequences were also found in CMT at similar frequencies 
in normal, benign and malignant CMTs, suggesting that MMTV is not causally associated 
with CMT [21]. Overall, the involvement of viruses in breast cancer, including IBC, remains 
unclear [75,76]. Given the influence of viruses in cancer [77], and in particular the oncogenic 
role of MMTV in murine mammary carcinogenesis [78-80], further research is warranted to 
determine the possible role of viruses in the malignant transformation of mammary gland 
cells of both dogs and humans. 
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3. Molecular biology of Inflammatory Breast Cancer  
3.1 Inflammatory microenvironment 
During carcinogenesis, malignant transformation is triggered by the accumulation of 
DNA mutations [81]. Some have suggested the high level of inflammation observed in IBC 
may serve to increase genetic instability and its associated DNA damage, promoting the 
malignant phenotype by increasing mutation rates [82,83].  
Considering IBC or CIMC as types of cancer with flaring inflammation, the 
expression of diverse cytokines and inflammatory mediators has been evaluated to determine 
their role in the severity of the disease. In CIMC, a study analyzing the presence of several 
cytokines in the serum and tissue homogenates of CIMC (n=7), malignant non-CIMC (n=24), 
mammary-gland hyperplasia (n=7) and benign tumors (n=10) reported higher IL-10 and IL-8 
serum levels in CIMC tumors than in the other groups, whereas in tumor-tissue homogenates, 
only IL-10 was significantly higher in CIMC than in the other groups, indicating a role for 
immunosuppression in the progression of CIMC [22]. One of the main limitations of this 
study was the low number of tumors present in each of the groups considered.  
Immunohistochemistry of tumors from 27 women with IBC found infiltration by 
CD14+ tumor-associated macrophages (TAMs) to be significantly more intense than in 
tumors from 39 women with non-IBC (IBC, 59.3% vs. non-IBC, 25.3%; P=.021). 
Additionally, in the same patient samples, cytokine profiling of the supernatant of CD14+ 
cells drained from axillary tributaries during surgery revealed significantly higher levels of 
TNF-α (P= .002), MCP-1/CCL2 (P= .003), IL-10 (P= .013), and IL-8 in IBC (P= .039) as 
compared to CD14+ TAMs isolated from the axillary tributaries of patients with non-IBC 
tumors  [33]. These authors have also shown that in vitro treatment with recombinant TNF-, 
IL-10 or IL-8 significantly increased motility and invasion of IBC cancer cell lines [33]. This 
fact adds value to the importance of the macrophage infiltration in IBC and how the secreted 
cytokines may contribute to increases in migration and invasion. Furthermore, Cohen and 
colleagues have demonstrated that treatment with T-cell and PBMC-conditioned media, rich 
in TNF-, IL-6 and TGF-β could induce epithelial to mesenchymal transition (EMT) in IBC 
cell lines SUM-149, SUM-190, IBC-3 and KPL-4 [84]. However, this study did not evaluate 
the role of T-cell secreted factors in vivo, in circumstances where cohesive E-cadherin 
overexpressing emboli form and where EMT does not have such a preponderant role in IBC 
metastasis. 
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These comparable observations suggesting a role for inflammatory cell infiltration 
and cytokine production in IBC and CIMC contribute to the growing body of evidence 
suggesting the value of CIMC as a model for the corresponding human disease [17]. The 
concept of TAMs and tumor-infiltrating T-cells as important elements in the establishment of 
a tumor-favorable microenvironment is also strengthened. Research on the role of cytokines 
and chemokines in the biological behavior of both IBC and CIMC could contribute to a better 
understanding of this disease and lead to the development of more efficient, targeted 
therapies to improve the current standard of care.  
 
3.2 Epithelial to mesenchymal transition (EMT) 
Extensive metastasis is a prominent aspect clinical progression of IBC and it is 
hoped that this will provide a target for novel therapies. Studies performed in IBC have 
explored the process of metastasis and the potential to identify new targets for intervention 
[36,37] with a focus on the mechanisms involved in epithelial to mesenchymal transition 
(EMT).  
TGF-β is a major inducer of EMT during embryological development, cancer and 
diseases involving chronic wound healing or fibrosis [85]. In response to TGF-β, many 
transcription factors regulating EMT are activated, including Twist1, SMAD, Zeb1 and 2 and 
Snail1 and 2 [85]. In IBC, however, EMT does not seem to have an important role in the 
process that enables cell migration and metastasis, given the lower levels of expression of 
TGFβ and the SMAD transcription factor in IBC versus non-IBC samples [60,86]. 
One hypothesis to explain the apparent EMT-independent migration and metastasis 
of IBC is that attenuation of TGF-β and in turn SMAD signaling causes a shift from single-
cell motility to a cohesive type of cluster migration with clustering mediated by E-Cadherin, 
leading primarily to the invasion of lymph vessels [60]. This hypothesis is supported by the 
differential expression of E-cadherin and the mechanisms involved in the cohesion of cells 
within emboli. E-cadherin overexpression is present in IBC models such as SUM149 and 
Mary-X, and constitutes part of a defined IBC molecular signature [36,87-91]. 
Overexpression of E-cadherin in IBC is seen in lymphovascular tumor emboli and in 
infiltrating tumor cells and seems to be involved in a metastatic process in which cohesion of 
cell clusters increases metastasis [37]. 
To confirm E-cadherin overexpression is responsible for the tight junctions inside of 
clusters, investigators used Mary-X, a human xenograft model of IBC, to show that E-
cadherin membrane expression contributes to an oncogenic effect while promoting metastasis 
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instead of suppressing it [92]. Specifically they observed the mechanism of E-cadherin 
overexpression was not transcriptional but instead related to altered protein trafficking. E-
cadherin protein levels were 5- to 10-fold higher,  but real-time RT-PCR, demonstrated E-
cadherin transcript levels in Mary-X were 3- to 11-fold less than in other E-cadherin positive 
human breast carcinoma lines These observations suggested altered E-cadherin trafficking 
contributes to its oncogenic rather than suppressive role in IBC. 
Cooperation between Sialyl Lewis x/a (sLex/a) under-expression and E-cadherin 
overexpression provided a molecular explanation for the formation of the lymphovascular 
emboli in the Mary X IBC model. Low sLex/a expression impedes adherence to the 
lymphovascular endothelium, and thus allows mobility of cell clusters. At the same time, the 
lack of electrostatic repulsion between sLex/a epitopes favors the maintenance of E-cadherin 
homodimers between cells increasing cellular cohesion [36].  
In CIMC cell lines, there has been limited characterization of sLex/a expression, but 
in the recently established IPC-366 CIMC cell line, E-cadherin and COX-2 overexpression 
were coupled with high proliferation rates, negative hormone receptors (PR, ER) and HER2 
[23]. In humans, COX-2 overexpression has been detected in the IBC cell line SUM149 and, 
it is suggested to drive celecoxib resistance in this cell line [34]. 
Finally, in both the MARY-X model and the CMT-U27 canine mammary carcinoma 
cell line, overexpression of E-cadherin and loss of Sialyl Lewis x (sLex) were observed in a 
heterogeneous cell population supporting the existence of interchangeable states of cohesion 
and repulsion between cells of tumor emboli to promote the metastatic process [91]. 
Comparative molecular biology aspects of CIMC and IBC are summarized in Table 3 
[22,33,36,84,85,91,93]. 
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Table 3 - The Biology and Molecular Biology of Human Inflammatory Breast Cancer (IBC) and Canine Inflammatory Mammary Carcinoma 
(CIMC)  
The Inflammatory Microenvironment 
Property and references CIMC IBC Comment  
Cytokines in serum and in 
lymph drainage 
[22], [33] 
 Higher IL-10 and IL-8 serum levels in 
CIMC tumors than in malignant non-
CIMC tumors, mammary-gland 
hyperplasia and benign tumors 
 Comparing the cytokine profile of the 
supernatant of CD14+ cells drained from 
axillary tributaries during surgery revealed 
significantly higher levels of TNF-α, 
MCP-1/CCL2, IL-10 and IL-8 in IBC as 
compared to patients with non-IBC tumors 
 Highlights the importance of 
macrophage infiltration in IBC 
and how secreted cytokines may 
contribute to migration and 
invasion 
Cytokines in tissues 
[33] 
 In tumor-tissue homogenates, only IL-10 
was significantly higher in CIMC than in 
malignant non-CIMC tumors, mammary-
gland hyperplasia and benign tumors 
 Immunohistochemistry to detect tumor-
associated CD14+ cells found higher levels 
in IBC than in non-IBC 
 Results suggest a role for 
immunosuppression in the 
progression of CIMC 
Cell lines 
[33,84] 
 No cell line studies  In vitro treatment with recombinant TNF-
, IL-10 or IL-8 significantly increased 
motility and invasion of IBC cancer cell 
lines 
 Treatment with media conditioned by T-
cells or PBMCs rich in TNF-, IL-6 and 
TGF-β induced EMT transition in four 
IBC cell lines SUM-149, SUM-190, IBC-3 
and KPL-4  
 Results suggest secreted 
cytokines may contribute to 
migration and invasion 
 Interpretation limited by lack of 
in vivo data, where cohesive E-
cadherin overexpressing emboli 
form and where the role of EMT 
in IBC metastasis may not be as 
prominent 
Epithelial to Mesenchymal Transition (EMT) 
TGFβ 
[36,60,85,91,93] 
 In CMT-U27 canine mammary 
carcinoma cells, overexpression of E-
cadherin and loss of Sialyl Lewis x 
(sLex) were observed in a heterogeneous 
cell population supporting the existence 
of interchangeable states of cohesion and 
repulsion between cells of tumor emboli 
to promote the metastatic process 
 
 TGF-β activates transcription factors 
regulating EMT  including SMAD.  
However TGFβ and SMAD expression are 
reduced in IBC versus non-IBC samples 
 Expression of E-cadherin and the 
mechanisms involved in the cohesion of 
cells have been found in tumor emboli 
 In the Mary-X cell line expression of E-
cadherin and loss of Sialyl Lewis x (sLex) 
contribute to metastasis 
 Interchangeable states of 
cohesion (E-cadherin) and 
repulsion [loss of Sialyl Lewis x 
(sLex)] between cells of tumor 
emboli can promote the 
metastatic process 
Abbreviations: CIMC, canine inflammatory mammary cancer; IBC, inflammatory breast cancer; EMT, epithelial to mesenchymal transition; TNFa, tumor 
necrosis factor alpha 
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4. Clinical Presentation and Pathologic/Histologic Findings 
In humans, IBC is a clinical diagnosis characterized by a rapid enlargement of the 
breast, changes in the overlying skin, with early erythematous discoloration and an orange-
peel appearance due to dermal edema (peau d’orange) with or without underlying discrete or 
palpable masses [46] (Figures 1A, B, C). These signs often cause misdiagnosis of an 
inflammatory or infectious process [27].  As in human IBC, the clinical presentation of CIMC 
can be wrongly diagnosed as mastitis or dermatitis due to extensive inflammation of the skin 
overlying the mammary glands, edema, as well as the pain involving the the axillary, 
mammary and inguinal regions (Figure 1D, E, F). Signs of generalized weakness, anorexia 
and metastasis have also been reported as significantly more frequent in CIMC than in other 
mammary tumor types [16].  
In humans, primary IBC develops de novo in a previously normal breast (Figure 
1B); while secondary IBC is characterized by a distinct presentation of the disease, with a 
diffuse chest wall rash or nodules that may quickly form ulcers (Figure 1A and C). This form 
of IBC can be present in patients with a history of non-inflammatory disease in the chest wall 
[27]. Another presentation of IBC, termed clinically occult, is described by the absence of 
clinical signs of inflammation in patients with aggressive breast cancer with histologically 
confirmed invasion of the dermal lymphatics by tumor emboli [94]. As in humans with a 
diagnosis of IBC, two clinical forms of CIMC have been described in companion dogs. 
Primary CIMC develops without a previous history of mammary nodules, while secondary 
CIMC occurs after a diagnosis of a mammary tumor, generally forming at the surgical wound 
site [16]. Two histological patterns of neoplastic dermal infiltration – tubular/papillary and 
sarcomatous-like – have been observed in CIMC [19]. Finally, histological types might 
differ, but are generally diagnosed as locally advanced invasive carcinoma of the breast in 
humans or as anaplastic carcinomas in dogs.  
In both species, the histological hallmark of inflammatory carcinomas is the 
formation of tumor emboli in dermal lymphatics resulting in profuse edema due to the 
obstruction of lymph drainage (Figure 2A and B). While emboli are characteristic of IBC, 
they are not specific [95]. For a correct diagnosis of inflammatory carcinoma, the 
histopathological diagnosis must be combined with the observation of clinical signs related to 
exuberant inflammation – tenderness, redness, edema, warmth, firmness [20,28] Dermal 
emboli in IBC patients are generally numerous and larger than in patients with non-IBC even 
though these characteristics present no correlation with the degree of breast-skin redness [5]. 
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In a retrospective study of Algerian IBC patients, 77% presented dermal emboli, although the 
presence of tumor emboli was not associated with lymph node metastasis or overall survival 
[63]. However, the presence of tumor emboli, in 70% of IBC cases (25% local IBC, 45% 
diffuse IBC; P=.01), was associated with diffuse presentation and 3-fold higher risk of 
relapse in a study of French-Tunisian IBC patients [96]. 
Finally, mild to moderate lymphoplasmocytic infiltration may be noted around some 
of the lymphovascular perivascular space [20,27]. Recent data have shown statistically 
significant increases in tumor-infiltrating lymphocytes in IBC patients, relative to non-IBC, 
and associations with TNBC status and pathologic complete response to neoadjuvant 
chemotherapy [97,98] 
Vasculogenic mimicry, the formation of vascular channels lined by tumor cells 
mimicking endothelial cells, is another characteristic identified in both IBC and CIMC 
[99,100], and it seems to reflect the exuberant angiogenic events taking place. In WIBC-9 
xenografts, a model of human IBC, vasculogenic mimicry, induced by angiogenic factors, 
was identified in hypoxic areas at the center of the tumors where vascular channels form 
independently of endothelial cells[99] . Studies have highlighted the intensive 
lymphangiogenesis and angiogenesis, contributing to the high metastatic potential of IBC 
[17,37,51,101] and CIMC [19,102,103]. To illustrate this, expression of CD31, an endothelial 
cell marker used to evaluate microvessel density as a measurement of neoangiogenesis, is 
shown for both IMC and CIMC in Figure 2, C and D respectively. A summary of 
comparative clinical signs, histologic and pathologic findings in CIMC and IBC is presented 
in Table 4 [17,19,20,27,37,51,94,99-103] 
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Table 4: Clinical Presentation and Pathologic/Histologic Findings 
Variable CIMC IBC 
Clinical diagnosis  Rapid painful enlargement of breast 
 Early erythematous discoloration and an orange-
peel appearance due to the dermal edema (peau 
d’orange) 
 With or without underlying discrete or palpable 
masses 
 Inflammation that can be wrongly diagnosed as mastitis or 
dermatitis due to extensive inflammation of the skin 
overlying the mammary glands 
 Edema 
 Suggestion of increased sensitivity over the axillary, 
mammary and inguinal regions 
Clinical history  Primary CIMC: Develops without a previous 
history of mammary nodules 
 Secondary CIMC: Occurs after a diagnosis of a 
mammary tumor, generally forming at the 
surgical wound 
 Primary IBC: Develops de novo in a previously normal 
breast 
 Secondary IBC: Characterized by diffuse chest wall rash or 
nodules that may quickly form ulcers [27] 
 A clinically occult presentation can occur with absence of 
clinical signs of inflammation in patients with aggressive 
breast cancer with histologically confirmed invasion of the 
dermal lymphatics by tumor emboli [94] 
Histology – Tumor emboli in dermal 
lymphatics 
 In both species, the histological hallmark is tumor emboli in dermal lymphatics leading to edema due to lymphatic 
obstruction. Lymphoplasmocytic infiltration may be seen in some lymphovascular/perivascular spaces [20,27] 
Histology – Vasculogenic mimicry  Vasculogenic mimicry (formation of vascular channels with tumor cells mimicking endothelial cells) seen in both 
IBC and CIMC [99,100] 
Histology – Lymphangiogenesis and 
angiogenesis 
 Intensive and contribute to the high metastatic potential of IBC [17,37,51,101] and CIMC [19,102,103] 
Histology – Immune infiltrates  Not yet reported  Recent data have shown statistically significant increases in 
tumor-infiltrating lymphocytes in IBC patients 
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5. Clinical management 
5.1 Standard of care treatment 
Currently, for patients diagnosed with IBC, a multidisciplinary treatment involves 
(1) neoadjuvant systemic therapy with a taxane plus anthracycline chemotherapy adding a 
HER2 targeted therapy for HER+ tumors; (2) followed by total mastectomy with level l/ll 
axillary dissection; and (3) adjuvant radiation therapy to the chest wall and draining 
lymphatics; with (4) possible delayed breast reconstruction and (5) completion of 
chemotherapy if not completed pre-operatively with endocrine therapy if either ER or PR 
positive and possible continuation of HER2-directed therapy [45]. Alternative therapeutic 
options have been suggested, including preoperative primary systemic chemotherapies with a 
docetaxel-epirubicin protocol with curative intent, which was demonstrated to lead to 
equivalent outcomes as anthracycline-containing protocols [104]. A 20-year follow-up study 
has also evaluated the possibility of combining only chemotherapy plus hormonal therapy 
and radiation in cases of nonmetastatic IBC, maintaining survival rates comparable to the 
standard-of-care treatment [105].  
The preferred treatment option for CMT is the surgical excision of the mammary 
glands [26]. However, for CIMC, as with invasive mammary carcinomas, neoadjuvant 
chemotherapy and/or palliative treatments might be preferable. Due to the diffuse 
presentation of CIMC and extensive inflammation, with difficult definition of surgical 
margins, incomplete excision is a risk too frequently taken [106].  
There is no consensus for a neoadjuvant chemotherapy protocol for CIMC. One 
clinical study revealed a clinical benefit on the prognosis of dogs with CIMC treated with 
piroxicam, a nonselective COX-2 inhibitor, alone or in combination with other 
chemotherapeutic drugs such as carboplatin, doxorubicin, capecitabine or cisplatin [6]. A 
positive response to piroxicam treatment was also observed in a group of 7 dogs with CIMC, 
in which the CIMC-associated clinical signs were visibly reduced and survival times 
increased relative to doxorubicin-treated animals [107]. Another study explored the effect on 
the overall survival time in dogs undergoing palliative treatment with piroxicam and 
antibiotics versus a combination of palliative and chemotherapeutic treatments combining 
mitoxantrone, vincristine and cyclophosphamide intravenously or giving mitoxantrone alone. 
No statistically significant differences were observed between the two groups, although dogs 
given chemotherapeutic treatment had longer mean survival times (57 days) than dogs on 
palliative treatment (32 days) [108]. However, large-scale clinical trials are needed to validate 
these different modalities and establish guidelines for recommended therapeutic approaches 
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for CIMC. Despite short overall survival, improved quality of life and slightly slower disease 
progression were observed with metronomic chemotherapy protocols using chlorambucil and 
firocoxib (a selective COX-2 inhibitor) [109]. 
5.2 Targeted therapies 
Targeted treatments in humans have included both small molecule inhibitors and 
monoclonal antibody therapies.  As an example, neoadjuvant anti-VEGF monoclonal 
antibody therapy with bevacizumab has been explored in combination with trastuzumab in 
the treatment for HER2-positive IBCs [110]. The preliminary results of a phase 2 clinical trial 
of primary IBC, that administered chemotherapy and radiotherapy with neoadjuvant 
bevacizumab plus trastuzumab, has demonstrated good tolerability and efficacy with 98% of 
patients achieving a clinical response with regression of inflammatory clinical signs 
associated with IBC [47].  
Additionally, due to expression of EGFR in nearly 30% of IBC cases and its 
association with a poor outcome [111], panitumumab, a fully human monoclonal antibody 
targeting EGFR is under evaluation in a phase II trial among patients with a diagnosis of IBC 
patients (NCT01036087). Accrual began in 2010 and at the end of 2017 final results were 
still not yet available underscoring the difficulty recruiting such a select group of patients. 
New therapeutic targets have been suggested arising from observations of IBC cell 
lines and tumor samples obtained from patients. Altered copy numbers of the anaplastic 
lymphoma kinase (ALK) gene have been detected in IBCs , and the susceptibility to 
crizotinib, an ALK and ROS1 inhibitor, was proven using mice bearing IBC xenografts. In 
the MaryX model Crizotinib induced apoptosis and reduced ALK expression [112]. The 
efficacy of this regimen in IBC will need to be explored.. Other potential therapeutic targets 
currently under preclinical investigation in IBC are E-cadherin and RhoC GTPase, therapies 
that ideally would be integrated in large-scale, multicenter cohort studies [5]. However, 
positive preclinical evaluations in cell lines and rodent models are often difficult to translate 
into positive clinical benefit in patients. This suggests that a more appropriate model system, 
such as dogs with CIMC, may be valuable as a more predictive preclinical model. 
To our knowledge there are no targeted therapies available for dogs with CIMC, 
albeit this reality could be transformed in coming years with the development of personalized 
antibody therapy for canine patients. Recent data showing an acceptabel safety profile with 
the anti-PD1 and PD-L1 monoclonal antibody-therapy used in humans with very limited 
activity in heavily pretreated advanced, triple-negative breast cancer [113,114],offers dogs as 
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a possible model for evaluating immunotherapy combinations with hopefully greater activity 
[115]. Preliminary studies assessing PD-L1 and PD1 expression in a wide range of canine 
malignancies, has found PD-L1 positivity in malignant CMT among others, suggesting 
assessment of the PD-1/PD-L1 axis as a therapeutic target can be pursued, particularly for 
canine oral melanoma where PD1 expressing T-cells were also observed. [116,117]. 
Following the recent trend in human cancer immunotherapy, most therapeutic monoclonal 
antibodies in veterinary oncology remain under investigation and pre-clinical development 
[118]. Presently, the FDA has only licensed anti-CD20 and CD52 chimeric monoclonal 
antibodies for treatment of canine B and T-cell lymphomas, respectively[119]. Progress 
toward improved therapeutic options for CIMC will require clinical studies able to test 
combination protocols and novel therapeutic targets. A summary of the clinical management 
options for CIMC and IBC is presented in Table 5 [6,26,45,47,106,110-112] 
 
Table 5 - Clinical management 
Intervention CIMC IBC 
Standard treatment of care  Surgical excision of affected 
mammary glands, except on 
diffuse presentation [26,106] 
 No consensus on 
neoadjuvant therapy. Use of 
COX-2 inhibitors alone or in 
combination with chemotherapy 
has been reported[6,110-112] 
 Multidisciplinary treatment with  
taxane-anthracycline-based 
neoadjuvant chemotherapy, followed 
by modified radical mastectomy and 
adjuvant radiation therapy to the 
chest wall and draining lymphatics 
[45] 
 
Targeted therapies  Research and development 
of targeted therapies for CIMC is 
still ongoing. 
 Neoadjuvant anti-VEGF 
(bevacizumab) plus trastuzumab in 
HER2-positive cases [47,110] 
 Anti-EGFR (panitumumab) 
under evaluation in clinical trial 
(NCT01036087). 
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6. Prognostic factors 
Despite the increased understanding of IBC and the multidisciplinary therapeutic 
approach, women diagnosed with IBC continue to have mortality rates that are higher than 
those women with non-inflammatory locally advanced breast cancer [5,111,120]. Similarly, 
the prognosis for dogs with CIMC remains poor and overall survival times range between 
weeks to only a few months [6,16]. Dogs receiving chemotherapeuty plus and a non-selective 
COX-2 inhibitor have shown significantly increased survival times relative to dogs receiving 
only palliative treatment [6]. However, large-scale clinical trials are warranted to confirm 
these findings in CIMC. A summary of the prognostic factors in IBC and suggested 
biomarkers warranting prognostic studies in CIMC is presented on table 6. Prognostic studies 
in dogs with CIMC are challenging due to the fact that most animals will eventually be 
euthanized given the severity of the clinical signs presented, instead of dying from advanced 
metastatic disease.  
 
6.1 Endocrine and HER2 receptors, chemokine receptors and epidermal growth factors 
In many cases of IBC, the triple-negative status drastically limits the treatment 
options and impacts negatively impacts patient prognosis [48]. In a retrospective study 
analyzing of 2,014 women diagnosed with IBC, hormone receptor (ER, PR) positive status 
was found to be associated with improved overall survival and breast cancer-specific survival 
(N=626; HR=0.55, 95% CI=0.47-0.65; P<.05) whereas HER2-positive status (N=703; 
HR=0.82, 95% CI = 0.68 to 0.99, NS) was not [125]. Other authors have confirmed the lack 
of prognostic value of HER2 receptor in IBC [121,122]. However, in patients with HER2-
positive tumors, treatment with trastuzumab confers benefit and improved survival times 
compared to HER2-negative patients [121]. It is possible that other molecules in IBC, such as 
E-cadherin [92,123], RhoC GTPase and WISP3 [39,124,125] may have a greater role in the 
mechanisms of IBC metastatic invasion, angiogenesis and tumor growth than the HER2 
receptor and that targeting these molecules could have a greater impact on the prognosis.  
Expression of the chemokine receptors CCR7 and CXCR4, previously associated 
with breast cancer metastasis [126] has been characterized in IBC. In one study, 40.9% and 
23%  of IBC cases had expression of CXCR4 and CCR7, respectively.. However, only 
concurrent expression levels of CXCR4 and CCR7 was associated with a trend for shorter 
overall survival, and this did not reach statistical significance [50].  
EGFR pathway activity, defined as the aggregate expression of a group of genes 
linked to EGFR signaling, is significantly lower in IBC patients who achieve a complete 
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pathological response than in those with residual disease after neoadjuvant, anthracycline-
based chemotherapy (P=.02)[93]. In CIMC, EGFR protein expression is high in tumor tissue 
homogenates and significantly increased relative to malignant CMT, benign CMT and non-
neoplastic mammary gland (P<.001). Therefore, incremental EGFR expression is proposed to 
have a role in the development of CIMC, but this hypothesis needs to be investigated 
mechanistically [127]. Representative EGFR expression in IBC and CIMC cases is shown on 
Figure 2 G and H, respectively.  
 
6.2 Cyclooxygenase-2 
The cyclooxygenase-2 (COX2)/prostaglandin E2 pathway is widely recognized for 
its role in driving mammary carcinogenesis as an inflammatory mediator and as a promoter of 
angiogenesis, metastasis and invasion in rodent models of mammary carcinogenesis 
[128,129]. In IBC, however, COX-2 expression and its prognostic value have been 
understudied. In vitro experiments have shown higher COX-2 expression in cancer stem cell 
tumorspheres of the IBC cell line SUM149 relative to the non-IBC cell line MCF-7, 
suggesting a role for COX-2 in stem cell formation and possibly a role in the inflammatory 
microenvironment of IBC [130]. In CIMC, high levels of COX-2 have been found relative to 
non-CIMC tumors [18]. There is a positive association of COX-2 with high VEGF-D and 
VEGFR levels, and the lymphatic proliferation index, supporting the involvement of COX-2 
in the lymphangiogenic mechanisms of CIMC [131]. Illustrative expression of COX-2 in IBC 
and CIMC is shown in Figure 2, images E and F respectively. 
 
6.3 Vascular endothelial growth factor 
Because IBC and CIMC require high levels of angiogenesis as part of their rapidly 
growing and invasive phenotype [37,101], it was expected that the expression of vascular 
endothelial growth factor (VEGF-A) is expected to be high. Interestingly, high expression of 
VEGF-A was found but this was noted in the stromal, but not in the epithelial cells of the 
tumor, and this was associated with poor disease-free and breast cancer-specific survival in 
patients with a diagnosis of IBC [51]. In CIMC, augmented tumoral VEGF expression has 
been reported, but its prognostic value has not been evaluated [102,131,132].  
 
6.4 Other prognostic factors 
More recently, innovative techniques have been applied to allow earlier prediction of 
metastatic risk in IBC patients. One study explored the predictive value of microscopic image 
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analysis of histopathology sections at the time of diagnosis [133]. By applying the Gray-
Level Co-Occurrence Matrix (GLCM) method, parameters of tissue heterogeneity, such as 
entropy and contrast, were able to predict metastasis outcome more efficiently than 
commonly used clinical variables. This technique could help to prioritize and select patients 
with higher metastatic risk for targeted therapies.  
Additionally, the number of circulating tumor cells (CTCs) (1) in patients with 
stage III IBC patients has also been identified as a good predictor of recurrence after primary 
systemic therapy, modified radical mastectomy, postoperative  radiotherapy and trastuzumab 
neoadjuvant treatment for HER2+ patients [134]. If further confirmed,  CTCs could be used to 
select patients at high risk of relapse. While the presence and prognostic role of CTCs in 
CIMC is unknown, the findings in humans with IBC warrant studies in CIMC. 
Table 6 - Prognostic factors 
 CIMC IBC 
Endocrine and HER2 receptors 
 
   ER+PR+ cases have improved 
outcomes, but not HER2+ 
[125] 
Chemokine receptors 
 
   Concurrent CXCR4 and 
CCR7 expression associated 
with trend in shorter OS [50]. 
Epidermal growth factor (EGFR)  Role for EGFR in CIMC 
progression has been suggested 
but prognostic studies are 
warranted [127] 
 EGFR pathway activity is 
lower in patients with 
complete pathological 
response [93] 
Cyclooxygenase-2 (COX-2)  COX-2 associated with 
VEGFR levels, and the lymphatic 
proliferation index, supporting the 
involvement of COX-2 in the 
lymphangiogenic mechanisms of 
CIMC [131]. Prognostic studies 
are warranted 
 Prognostic studies are 
warranted 
VEGF  Tumoral VEGF is expressed 
in CIMC but prognostic value has 
not been assessed [102,131,132] 
 Stromal VEGF-A associated 
with poor DFS and BCSS 
[51] 
Others   Entropy, contrast and other 
parameters of tissue 
heterogeneity can predict 
metastasis[133]. 
 CTCs1 predicts recurrence 
in HER2+ IBC patients after 
multimodal therapy [134]  
OS - overall survival, DFS - disease free survival, BCSS - breast cancer specific survival, CTCs - 
Circulating tumor cells 
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7. Conclusion and future perspectives (5-year horizon) 
For both humans and dogs, the aggressiveness and lethality of IBC and CIMC, 
compared to other breast cancer types demands a concerted multidisciplinary effort to 
identify novel and specific therapeutic options and prognostic factors to help categorize 
patients and provide better treatments. The fundamental similarities between human IBC and 
CIMC underlie the value of comparative and translational research for the benefit of both 
species. Advances in understanding the pathogenesis of both diseases and the development of 
genome-based molecular and immunological reagents, as well as commercially available 
high-throughput methodologies such as next-generation sequencing or multiple-cytokine 
array assays specific for dogs, will enhance our ability to deeply interrogate canine cancers 
and characterize shared and novel targets for novel therapeutic interventions.  
A major challenge of therapeutic development in oncology is the design of clinical 
trials, often based solely on previous research using rodent models. We would argue CIMC 
could serve as an intermediate preclinical model between rodent models and humans prior to 
the design and execution of clinical trials. A canine preclinical model could enable a better 
understanding of the mechanism of action of a novel intervention, dosing, administration and 
could potentially improve clinical trial design and hopefully increase success rates while 
reducing expense. Furthermore, the development of therapies in canines would also serve the 
animal patients and their owners. Current therapies for canine cancers, as noted above for 
CIMC, are often not a cost-effective option. The opportunity to perform well-designed and 
innovative therapy trials at minimal expense for dog owners and researchers would provide 
canine patients and their owners access to the best therapeutic options while also contributing 
to improvement in the therapy of human cancer. Additional advantages to using a 
spontaneous canine model in preclinical studies include the short lifespan after diagnosis that 
offers the opportunity to accelerate endpoints of clinical trials and the exposure to 
environmental pollutants that renders dogs as suitable sentinels. While not advocated as a 
replacement for toxicokinetic studies in rodent models, comparative oncology studies 
performed in dogs have the potential to provide information not easily obtained by 
conventional preclinical models prior to human trials [2]. Finally, the existence of CIMC cell 
lines might facilitate in vitro screening of new therapeutic drugs in preclinical studies for 
CIMC [23],providing another strategy to further reduce the time and cost of preclinical 
development. Although testing of novel CIMC therapies can begin immediately, CIMC as a 
model for IBC could be further optimized with additional comparative studies evaluating 
immunohistochemical expression of prognostic markers and gene expression profiles. 
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 We envision that immunotherapeutic strategies will start to be employed for the 
treatment of canine cancers, including CIMC. In these animals, genetically variable tumors 
develop spontaneously in a syngeneic environment and in the presence of an intact immune 
system in an aging animal, thus making dogs diagnosed with CIMC ideal models to research 
new treatments for this highly metastatic and deadly tumor. Upcoming production of novel 
therapeutic monoclonal antibodies against biomarkers with prognostic significance could 
rapidly provide dogs with state-of-the-art therapy and, in parallel, generate clinically relevant 
new data with direct applicability to subsequent human clinical trial studies.  
Given the highly metastatic nature of IBC and CIMC, knowledge obtained about this 
cancer type could be applied to the management of other highly aggressive epithelial cancer 
types. In addition, the discovery of new therapeutic targets may provide new opportunities for 
the treatment of this aggressive disease in both humans and canines. Prospectively, further 
research is warranted for a better understanding of the biology of IBC and CIMC by 
identification of specific molecular determinants and the subsequent innovative design of 
targeted therapies that could halt the metastatic process and hopefully improve outcomes for 
patients with both IBC and CIMC.  
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Figure 1 - Fig.1 - Clinical presentation of human IBC with redness, edema, and 
erythema; the site of the incisional biopsy is shown above the nipple (A). Bilateral IBC with 
similar symptoms as in A, and peau d’orange or orange peel appearance (B). Local 
recurrence of IBC. Note the scarf of the mastectomy from the primary IBC marked with an 
asterisk (C).Clinical presentation of canine IMC with extensive inflammation and edema of 
mammary (D) and inguinal region (E), and erythema and pustules (F). Secondary CIMC 
(previous incision marked with asterisk) (D) primary CIMC (E and F).  
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Fig.2 - Invasion of dermal lymphatic vessels by IBC (A) and CIMC emboli (B). 
CD31 expression in endothelial cells of lymphatic and blood vessels in IBC (C) and CIMC 
(D), indicated by arrowheads. COX-2 expression in IBC (E) and CIMC emboli (F). 
Expression of EGFR on the cell membrane and cytoplasm in IBC emboli (G) and CIMC 
emboli (H).  
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